The production capacity of the enterprise is up to 80 mln doses of sterile pharmaceutical products per year. Production is carried out on the basis of the following manufacturing complexes:
Recombinant products
Production of the COVID-19 vaccine Convacell®, a recombinant component of the vaccine for the prevention of meningococcal infections
Production of tuberculosis allergen and conjugate vaccines (vaccines for prevention of pneumococcal, meningococcal and hemophilic infection type b «Baby-Hib»)
Finished dosage forms
Modern fill and finish (ampoules, vials, lyophilization of solutions in vials)
Three production technology platforms
Developer of vaccines for the national Calendar of Preventive Vaccinations of the Russian Federation
